Drug Trial Radar · NCT06471218
Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia
Last checked: Nov 19, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44
Actual
Start
Jul 2, 2024
Primary completion
May 16, 2025
Study completion May 16, 2025
Sponsor
- Lead sponsor
- Beijing Suncadia Pharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluation of the efficacy and safety of multiple subcutaneous injections of SHR-1918 in patients with hyperlipidemia in poor control: a multicenter, randomized, double-blind, placebo-controlled phase II clinical trials
Conditions
- Hyperlipidemia
Interventions
SHR-1918; SHR-1918 PlaceboDrug
SHR-1918/SHR-1918 Placebo,two administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change in calculated LDL-C from baseline to week 24Time frame: from baseline to week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Meizhou People's Hospital
Meizhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.